News & Updates

Show Multimedia Only
Prophylactic anticoagulants, pharmacy oversight lower VTE risk in multiple myeloma

Prophylactic anticoagulants, pharmacy oversight lower VTE risk in multiple myeloma

06 Apr 2022

Treatment with a guideline-based thromboprophylaxis in multiple myeloma patients and the addition of pharmacy oversight to risk assessment can help reduce the risk of venous thromboembolism (VTE), suggests a recent study.

06 Apr 2022
Relapsed/refractory multiple myeloma patients burdened with poor survival, high costs

Relapsed/refractory multiple myeloma patients burdened with poor survival, high costs

06 Apr 2022

Patients with relapsed/refractory multiple myeloma (RRMM) are at greater risk of adverse events (AEs), have low overall survival (OS), and suffer a substantial economic burden, reports a study, which suggests the need for effective treatment options.

06 Apr 2022